On March 6, 2018 Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), reported that Walter Klemp, chief executive officer and Jon Foster, chief financial officer, will present at the 30th Annual ROTH Conference on Tuesday, March 13, 2018 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) in Yellow – Salon 6 (Press release, Moleculin, MAR 6, 2018, View Source [SID1234524456]). The conference is being held at the Ritz-Carlton Hotel in Dana Point, California from March 11-14, 2018.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A webcast of the presentation will be available at the Investor Relations page of the Company’s website at www.moleculin.com. The webcast and presentation will be archived on the Company’s website for 90 days following the event.
The Company will also host investor meetings throughout the day on Tuesday, March 13, 2018. Attendance at the conference is by invitation only for clients of ROTH Capital Markets. Interested investors should contact your ROTH Capital Markets sales representative or Lytham Partners at (602) 889-9700 or [email protected] to secure a meeting time.